Prognostic value of Interleukin-36s in cancers: A systematic review and meta-analysis

IF 3.7 3区医学 Q2 BIOCHEMISTRY & MOLECULAR BIOLOGY

Cytokine Pub Date : 2023-11-01 DOI:10.1016/j.cyto.2023.156397

Rui Zhang , Mengyuan Jiang , Min Huang , Jing Yang , Qianqian Liu , Ziru Zhao , Yuping Bai , Tingting He , Dengcai Zhang , Min Zhang

{"title":"Prognostic value of Interleukin-36s in cancers: A systematic review and meta-analysis","authors":"Rui Zhang , Mengyuan Jiang , Min Huang , Jing Yang , Qianqian Liu , Ziru Zhao , Yuping Bai , Tingting He , Dengcai Zhang , Min Zhang","doi":"10.1016/j.cyto.2023.156397","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Interleukin-36s (IL-36s) are a category of inflammatory cytokines and an increasing number of studies over the past decade have found that different kinds of IL-36s play different roles in cancers. This systematic review and <em>meta</em>-analysis aimed to evaluate the prognostic value of IL-36s in different cancer types.</p></div><div><h3>Method</h3><p>Two reviewers independently searched in PubMed, Cochrane Library and EMBASE up to December 13, 2022. We extracted the hazard ratio (HR) and the confidence intervals (CIs) of the related prognostic outcomes and analyzed the pooled HR.</p></div><div><h3>Results</h3><p>We included 12 studies including 1925 patients. In all, six studies including IL-36α, five including IL-36γ and one including IL-36β. A high expression of IL-36α was associated with better overall survival (OS) (HR = 0.48, 95 %CI: 0.37–0.62, <em>P</em> < 0.001) of cancer patients. The expression of IL-36γ was not related with cancers. Further, subgroup analysis showed that the expression of IL-36γ had no correlation with the OS of colorectal cancer (CRC) and non‑small cell lung cancer (NSCLC) patients. Interestingly, a high expression of IL-36γ played contrasting prognostic roles in hepatocellular carcinoma (HCC) (HR = 0.43, 95 %CI: 0.27–0.69, <em>P</em> < 0.001) patients and gastric cancer (GC) (HR = 1.58, 95 %CI: 1.33–1.87, <em>P</em> < 0.001) patients. The only IL-36β related study showed the expression of IL-36β was not correlated with the prognosis of CRC patients (<em>P</em> > 0.05).</p></div><div><h3>Conclusion</h3><p>IL-36α, IL-36β and IL-36γ possibly play different roles in different cancers. High expression of IL-36α may be associated with good prognostic value in cancer patients, especially in CRC patients. The association between cancers prognosis and expression of IL-36β or IL-36γ needs further evaluation. These conclusions need more clinical prognostic data for confirmation.</p></div>","PeriodicalId":297,"journal":{"name":"Cytokine","volume":"172 ","pages":"Article 156397"},"PeriodicalIF":3.7000,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1043466623002752/pdfft?md5=1f2c25d5d1e8b4e0a4f07f3818c1a84f&pid=1-s2.0-S1043466623002752-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cytokine","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1043466623002752","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Interleukin-36s (IL-36s) are a category of inflammatory cytokines and an increasing number of studies over the past decade have found that different kinds of IL-36s play different roles in cancers. This systematic review and meta-analysis aimed to evaluate the prognostic value of IL-36s in different cancer types.

Method

Two reviewers independently searched in PubMed, Cochrane Library and EMBASE up to December 13, 2022. We extracted the hazard ratio (HR) and the confidence intervals (CIs) of the related prognostic outcomes and analyzed the pooled HR.

Results

We included 12 studies including 1925 patients. In all, six studies including IL-36α, five including IL-36γ and one including IL-36β. A high expression of IL-36α was associated with better overall survival (OS) (HR = 0.48, 95 %CI: 0.37–0.62, P < 0.001) of cancer patients. The expression of IL-36γ was not related with cancers. Further, subgroup analysis showed that the expression of IL-36γ had no correlation with the OS of colorectal cancer (CRC) and non‑small cell lung cancer (NSCLC) patients. Interestingly, a high expression of IL-36γ played contrasting prognostic roles in hepatocellular carcinoma (HCC) (HR = 0.43, 95 %CI: 0.27–0.69, P < 0.001) patients and gastric cancer (GC) (HR = 1.58, 95 %CI: 1.33–1.87, P < 0.001) patients. The only IL-36β related study showed the expression of IL-36β was not correlated with the prognosis of CRC patients (P > 0.05).

Conclusion

IL-36α, IL-36β and IL-36γ possibly play different roles in different cancers. High expression of IL-36α may be associated with good prognostic value in cancer patients, especially in CRC patients. The association between cancers prognosis and expression of IL-36β or IL-36γ needs further evaluation. These conclusions need more clinical prognostic data for confirmation.

查看原文本刊更多论文

白细胞介素-36s在癌症中的预后价值：一项系统综述和荟萃分析。

背景：白细胞介素-36s（IL-36s）是一类炎症细胞因子，在过去的十年中，越来越多的研究发现不同种类的IL-36s在癌症中发挥着不同的作用。本系统综述和荟萃分析旨在评估IL-36在不同癌症类型中的预后价值。方法：截至2022年12月13日，两名评审员在PubMed、Cochrane Library和EMBASE中独立检索。我们提取了相关预后结果的风险比（HR）和置信区间（CI），并分析了合并的HR。结果：我们纳入了12项研究，包括1925名患者。总共有6项研究包括IL-36α，5项包括IL-36γ，1项包括IL-6β。IL-36α的高表达与总生存率（OS）的提高有关（HR=0.48，95%CI:0.37-0.62，P 0.05）。结论：IL-36α、IL-36β和IL-36γ在不同的癌症中可能发挥不同的作用。IL-36α的高表达可能与癌症患者，尤其是CRC患者的良好预后价值相关。肿瘤预后与IL-36β或IL-36γ表达之间的关系需要进一步评估。这些结论需要更多的临床预后数据来证实。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cytokine 医学-免疫学

CiteScore

7.60

自引率

2.60%

发文量

262

审稿时长

48 days

期刊介绍： The journal Cytokine has an open access mirror journal Cytokine: X, sharing the same aims and scope, editorial team, submission system and rigorous peer review. * Devoted exclusively to the study of the molecular biology, genetics, biochemistry, immunology, genome-wide association studies, pathobiology, diagnostic and clinical applications of all known interleukins, hematopoietic factors, growth factors, cytotoxins, interferons, new cytokines, and chemokines, Cytokine provides comprehensive coverage of cytokines and their mechanisms of actions, 12 times a year by publishing original high quality refereed scientific papers from prominent investigators in both the academic and industrial sectors. We will publish 3 major types of manuscripts: 1) Original manuscripts describing research results. 2) Basic and clinical reviews describing cytokine actions and regulation. 3) Short commentaries/perspectives on recently published aspects of cytokines, pathogenesis and clinical results.